<- Go Home
Precipio, Inc.
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.
Market Cap
$31.3M
Volume
11.3K
Cash and Equivalents
$2.3M
EBITDA
-$685.0K
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$10.2M
Profit Margin
44.82%
52 Week High
$22.38
52 Week Low
$3.90
Dividend
N/A
Price / Book Value
2.45
Price / Earnings
-23.65
Price / Tangible Book Value
13.02
Enterprise Value
$32.6M
Enterprise Value / EBITDA
-84.58
Operating Income
-$2.1M
Return on Equity
9.76%
Return on Assets
-6.82
Cash and Short Term Investments
$2.3M
Debt
$3.6M
Equity
$13.7M
Revenue
$22.8M
Unlevered FCF
$895.0K
Sector
Health Care Providers and Services
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium